OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Hematology & Oncology is 89. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	554
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	544
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	534
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	533
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	499
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	474
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial	432
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	383
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	359
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	357
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast	331
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	311
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	308
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation	304
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	300
Cancer vaccines: current status and future directions	283
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	278
Landscape of biallelic DNMT3A mutant myeloid neoplasms	278
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	274
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma	246
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	242
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	238
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	233
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	232
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	212

Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	209
Recent advances in therapeutic strategies for non-small cell lung cancer	204
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	190
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response	188
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	181
Personalized nanovaccines for treating solid cancer metastases	181
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	177
Ferroptosis: principles and significance in health and disease	174
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	172
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	165
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	162
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	162
Targeting CD47 for cancer immunotherapy	160
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	157
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	154
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	153
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer	151
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	146
3D chromatin architecture and transcription regulation in cancer	146
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	144
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1	139
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology	137
Recent advances in targeted strategies for triple-negative breast cancer	130
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	129
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	129
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	128
Small RNA modifications: regulatory molecules and potential applications	126
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	124
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	123
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers	121
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	119
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	118
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	118
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study	117
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	117
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	117
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	116
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	116
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	115
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	114
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	112
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	110
A single-cell and spatially resolved atlas of human osteosarcomas	110
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies	110
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	109
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	108
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target	106
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	106
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	106
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	105

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure	103
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth	99
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	98
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	97
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	97
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	97
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	96
HLA alleles associated with asparaginase hypersensitivity in Chinese children	95
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	95
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	95
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer	90
The functional and clinical roles of liquid biopsy in patient-derived models	90
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	89
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	89
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	89